Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Adagrasib targets a specific cancer-causing mutation, while VS-6766 interferes with multiple steps in a cell growth signaling pathway.
Women who took this drug in addition to standard chemotherapy lived longer than those who just received standard chemo.
Cancer Health spoke with the Foundation for Women’s Cancer about gynecologic cancer education, prevention and eradication.
A consortium of health providers and researchers hopes to raise public awareness of how exercise can benefit those living with cancer.
Keytruda plus Lenvima is first approval under Project Orbis collaboration.
Some of the most common and deadly cancers receive little attention and resources.
But much needs to be done to help cancer survivors live longer and healthier lives.
A genomic sequencing program revealed a genetic mutation that was able to be successfully treated with a checkpoint inhibitor.
Incidence is increasing for six of 12 obesity-related cancers, including colorectal, kidney and pancreatic.
Researchers concluded that “increased awareness and better early detection may improve endometrial cancer mortality going forward.”
Advances in external and internal radiation therapies allow for better-targeted dosing of tumors while minimizing exposure of normal tissue.
PapSEEK identifies cancer-related alterations in DNA obtained from fluids collected during a routine Pap test.
Inaugural Northwest Gynecological Cancer Symposium brings together scientists studying ovarian, cervical and endometrial cancers
Endometrial Cancer Incidence Rising in the US and Worldwide
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.